R Yarchoan

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha
    Victoria Wang
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9641. 2010
  2. pmc Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induction by hypoxia and hypoxia-inducible factors
    Ravindra P Veeranna
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    J Virol 86:1097-108. 2012
  3. ncbi Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity
    Robert Yarchoan
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1868, USA
    Crit Rev Immunol 27:401-14. 2007
  4. ncbi Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management
    Robert Yarchoan
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1868, USA
    Nat Clin Pract Oncol 2:406-15; quiz 423. 2005
  5. ncbi Therapy for Kaposi's sarcoma: recent advances and experimental approaches
    R Yarchoan
    HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    J Acquir Immune Defic Syndr 21:S66-73. 1999
  6. ncbi In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine
    R Yarchoan
    Clinical Oncology Program, National Cancer Institute, Bethesda, MD 20892
    Science 245:412-5. 1989
  7. ncbi Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex
    R Yarchoan
    Clinical Oncology Program, National Cancer Institute, Bethesda, MD 20892
    Lancet 336:526-9. 1990
  8. ncbi Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS
    C Chougnet
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 184:201-5. 2001
  9. ncbi Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study
    A Surbone
    Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland
    Ann Intern Med 108:534-40. 1988
  10. ncbi Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT)
    R Yarchoan
    National Cancer Institute, Bethesda, Maryland
    Lancet 1:76-81. 1988

Collaborators

Detail Information

Publications80

  1. pmc Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha
    Victoria Wang
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9641. 2010
    ..One was protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1). PTPRZ1 is overexpressed in a number of tumors and has been implicated in glioblastoma pathogenesis...
  2. pmc Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induction by hypoxia and hypoxia-inducible factors
    Ravindra P Veeranna
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    J Virol 86:1097-108. 2012
    ..These results provide evidence that hypoxia and HIFs upregulate both latent and lytic KSHV replication and play a central role in the life cycle of this virus...
  3. ncbi Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity
    Robert Yarchoan
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1868, USA
    Crit Rev Immunol 27:401-14. 2007
    ..IL-12 has also been found active in patients with certain lymphomas. These results suggest that IL-12 may be worth exploring further as a potential antitumor agent in selected tumors...
  4. ncbi Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management
    Robert Yarchoan
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1868, USA
    Nat Clin Pract Oncol 2:406-15; quiz 423. 2005
    ..There is currently an interest in developing new therapies for HIV-associated malignancies, based on viral, vascular or other pathogenesis-based targets...
  5. ncbi Therapy for Kaposi's sarcoma: recent advances and experimental approaches
    R Yarchoan
    HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    J Acquir Immune Defic Syndr 21:S66-73. 1999
    ..Effective anti-HIV treatment has been shown to affect the growth of KS, and the discovery of a new herpesvirus as a causative agent for KS has offered new potential targets for attack...
  6. ncbi In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine
    R Yarchoan
    Clinical Oncology Program, National Cancer Institute, Bethesda, MD 20892
    Science 245:412-5. 1989
    ..Further controlled studies to define the safety and efficacy of this agent may be worth considering...
  7. ncbi Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex
    R Yarchoan
    Clinical Oncology Program, National Cancer Institute, Bethesda, MD 20892
    Lancet 336:526-9. 1990
    ..5 patients with HIV-induced cognitive impairment improved with ddI. Thus, ddI may have anti-HIV activity at doses which are tolerated for long-term therapy, although pancreatitis could be a life-threatening complication...
  8. ncbi Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS
    C Chougnet
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 184:201-5. 2001
    ..These findings suggest that long-term nonsuppressive antiretroviral therapy can induce limited improvement in immune function in pediatric AIDS patients and that the effect of suppressive treatments should be investigated...
  9. ncbi Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study
    A Surbone
    Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland
    Ann Intern Med 108:534-40. 1988
    ..Data for this small group suggest that this drug combination can be tolerated in patients with severe HIV infections; this study can be used as a basis for larger studies of this drug combination...
  10. ncbi Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT)
    R Yarchoan
    National Cancer Institute, Bethesda, Maryland
    Lancet 1:76-81. 1988
    ..03 mg/kg every 4 h for 7 days). The regimen was well tolerated, and the 5 patients who completed 9 or more weeks of treatment had sustained rises in their T4+ T cells and/or falls in p24 antigen...
  11. ncbi Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders
    Y Aoki
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 97:2173-6. 2001
    ..Circulating vIL-6 levels were associated with HIV(+) status (P <.0001). However, within the HIV(+) cohort, serum vIL-6 levels were not associated with the occurrence of KSHV-associated malignancies (P =.43). (Blood. 2001;97:2173-2176)..
  12. ncbi Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI)
    S Aoki
    Division of Cancer Treatment, National Cancer Institute, National Institute of Health, Bethesda, MD 20892
    AIDS Res Hum Retroviruses 6:1331-9. 1990
    ..However, larger studies will be required to determine the sensitivity and specificity of this assay and further longitudinal studies will be essential...
  13. ncbi Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection
    N R Hartman
    Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Clin Pharmacol Ther 47:647-54. 1990
    ..The level of ddI in the cerebrospinal fluid 1 hour after drug infusion averaged 21% of that of the simultaneous plasma level. It is concluded that ddI has pharmacokinetic properties that are amenable to its clinical use...
  14. ncbi The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles
    R Yarchoan
    Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
    Rev Infect Dis 12:S522-33. 1990
    ..However, life-threatening pancreatitis is a possible complication even at low dosages, and the best ways to manage and avoid adverse effects are still under study...
  15. ncbi Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy
    J M Pluda
    National Cancer Institute, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland
    Ann Intern Med 113:276-82. 1990
    ..As improved therapies for the treatment of HIV infection and its complications result in prolonged survival, non-Hodgkin lymphoma may become an increasingly significant problem...
  16. ncbi Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy
    M A Polis
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Building 10, Room 11C103, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Lancet 358:1760-5. 2001
    ..75 or 1.00 log, respectively. We investigated the possibility of assessing drug efficacy from measurements of plasma HIV-1 concentrations made during the first week on therapy...
  17. ncbi A potential role for interleukin-7 in T-cell homeostasis
    T J Fry
    Pediatric Oncology Branch, Biostatistics and Data Management Section, and HIV and AIDS Malignancy Branch of the National Cancer Institute, The National Institutes of Health, Bethesda, MD, USA
    Blood 97:2983-90. 2001
    ..In light of the known effects of IL-7 on T-cell regeneration, we postulate that increased availability of IL-7 could play a critical role in restoring T-cell homeostasis following T-cell depletion...
  18. ncbi Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology
    Richard F Little
    Center for Cancer Research CCR, National Cancer Institute NCI, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:4653-9. 2003
    ..These results suggest that tumor pathogenesis is responsible for the improved outcome of ARLs in the era of HAART...
  19. pmc Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses
    V Blazevic
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Clin Diagn Lab Immunol 8:943-8. 2001
    ..Furthermore, these data indicate improvement in antigen-presenting cell immunological function in HIV-infected children induced by HAART...
  20. ncbi A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection
    B Y Nguyen
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    J Infect Dis 168:810-7. 1993
    ..This regimen appears to be generally tolerable and to have anti-HIV activity. Additional studies will be needed, however, to learn how to best combine the available agents in patients with HIV infection...
  21. ncbi Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy
    R F Little
    HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland, USA
    Curr Opin Oncol 12:438-44. 2000
    ..Major questions persist, however, on the role of chemotherapy dose intensity, the best use of antiretroviral therapy during the administration of lymphoma therapy, and the optimal design of studies that can address these questions...
  22. ncbi Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions
    Y Aoki
    Medicine Branch and HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 96:1599-601. 2000
    ..The results of the current study suggest that these cytokines play a central role in the pathogenesis and manifestations of PEL. (Blood. 2000;96:1599-1601)..
  23. ncbi Infection of mesothelial cells with human herpes virus 8 in human immunodeficiency virus-infected patients with Kaposi's sarcoma, Castleman's disease, and recurrent pleural effusions
    Peter Bryant-Greenwood
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Building 10, Room 2A19, Bethesda, MD, USA
    Mod Pathol 16:145-53. 2003
    ..Additional studies need to be done to define the role of mesothelial cell infection in the pathogenesis of these HHV 8-associated effusions and define the prognostic significance...
  24. ncbi Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC)
    R M Dubinsky
    Human Motor Control Section, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Maryland
    Muscle Nerve 12:856-60. 1989
    ..We believe that dideoxycytidine can be an axonal toxin, especially when given in high dose continuous regimens.(ABSTRACT TRUNCATED AT 250 WORDS)..
  25. pmc HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression
    I Stefanova
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Invest 98:1290-7. 1996
    ..Modification of T cell PTKs may thus underlie the HIV-induced impairment of lymphocyte function and may potentially predict disease progression...
  26. pmc Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions
    D A Davis
    HIV and AIDS Malignancy Branch, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Virol 73:1156-64. 1999
    ..This is consistent with the cysteines being involved in the regulation of viral maturation in cells under oxidative stress...
  27. ncbi Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro
    D A Davis
    HIV and AIDS Malignancy Branch, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 272:25935-40. 1997
    ..Our results implicate thioltransferase in the regulation and/or maintenance of protease activity in HIV-1 infected cells...
  28. ncbi Reversible oxidation of HIV-2 protease
    David A Davis
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Methods Enzymol 348:249-59. 2002
  29. ncbi Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis
    Lei Yao
    Experimental Transplantation and Immunology Branch, CCR, National Cancer Institute, National Institutes of Health, Bldg 10, Rm 12N226, MSC 1907, Bethesda, MD 20892, USA
    Blood 102:3900-5. 2003
    ....
  30. pmc Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma
    Richard F Little
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1868, USA
    Blood 110:4165-71. 2007
    ..A randomized trial of IL-12 in this setting may be warranted. This study is registered at (http://www.clinicaltrials.gov) as no. NCT00020449...
  31. pmc Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways
    A Blauvelt
    Dermatology Branch, National Cancer Institute, Bethesda, Maryland 20892 1908, USA
    J Clin Invest 100:2043-53. 1997
    ..We suggest that strategies designed to block mucosal transmission of HIV should consider interfering with both virus infection and virus capture by DC...
  32. ncbi Quantitative assessment of tumor vasculature and response to therapy in kaposi's sarcoma using functional noninvasive imaging
    M Hassan
    Laboratory of Integrative and Medical Biophysics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Technol Cancer Res Treat 3:451-7. 2004
    ..004 and 0.002 respectively). These techniques hold promise to assess physiologic parameters in KS lesions and their changes with therapy...
  33. pmc Cancer burden in the HIV-infected population in the United States
    Meredith S Shiels
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
    J Natl Cancer Inst 103:753-62. 2011
    ..We estimated the annual number of cancers in the HIV-infected population, both with and without AIDS, in the United States...
  34. pmc Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation
    David A Davis
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 105:4561-8. 2005
    ..Thus, in addition to its role as a regulator of the biologic activity of kinins and anaphylatoxins, CPN is an important regulator of the biologic activity of SDF-1alpha by reducing the chemokine-specific activity...
  35. pmc Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma
    Richard F Little
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1868, USA
    Blood 107:4650-7. 2006
    ..These results provide preliminary evidence that IL-12 has substantial activity against AIDS-related KS with acceptable toxicity and warrants further investigation for this indication...
  36. ncbi Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease
    David A Davis
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 10S255, NIH, Bethesda MD 20892 1868, USA
    Antiviral Res 72:89-99. 2006
    ..Although P27 was rationally designed to block dimerization of the mature HIV-1 protease, the effects of P27 on HIV-1 replication may be related to partial inhibition of Gag-Pol processing leading to a disruption in virus release...
  37. pmc Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma
    Peter D Burbelo
    Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 201:1919-22. 2010
    ..These results suggest that antibody responses to lytic and latent KS-associated herpesvirus antigens differ in these diseases...
  38. ncbi Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy
    Wendy B Bernstein
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1868, USA
    Int J Hematol 84:3-11. 2006
    ..Strategies for prevention, screening, and therapy remain important areas of research in this developing field...
  39. ncbi Noninvasive Multimodality Imaging Techniques to Assess Kaposi's Sarcoma
    Amir Gandjbakhche
    Lab of Integrative and Medical Biophysics, National Institute of Child Health and Human Development NICHD, National Institutes of Health NIH, Bethesda, MD 20892, USA Email
    Conf Proc IEEE Eng Med Biol Soc 1:694-6. 2005
    ..The techniques are objective, easy to perform, and appear to be very sensitive in assessing improvement in the lesions upon administration of therapy...
  40. ncbi Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen
    Rohan Hazra
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1868, USA
    Viral Immunol 20:131-41. 2007
    ....
  41. pmc Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach
    David A Davis
    HIV and AIDS Malignancy Branch, Retrovirology Disease Section, Center for Cancer Research, National Cancer Institute, Building 10, Room 6N106, NIH National Institutes of Health, Bethesda, MD 20892, USA
    Biochem J 419:497-506. 2009
    ..The present study is the first characterization of dimerization inhibition of PR(MDR), a prime target for these inhibitors, using a novel size-exclusion chromatographic approach...
  42. ncbi Using quantitative imaging techniques to assess vascularity in AIDS-related Kaposi's sarcoma
    Abby Vogel
    Laboratory of Integrative and Medical Biophysics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Conf Proc IEEE Eng Med Biol Soc 1:232-5. 2006
    ..These three techniques are objective, easy to perform, and appear to be very sensitive in assessing changes in the lesions upon administration of therapy...
  43. ncbi Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells
    David A Davis
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Cancer Res 67:7003-10. 2007
    ..These findings may have clinical applicability in the development of effective therapies for PEL or other KSHV-related malignancies...
  44. pmc Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation
    David A Davis
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:3319-25. 2003
    ..The regulation of protease activity by the modification of a sulfur-containing amino acid at the dimer interface may be a conserved mechanism among the majority of retroviruses...
  45. pmc Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages
    David A Davis
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 46:402-8. 2002
    ..These studies demonstrate that antiviral compounds can be susceptible to oxidative modification in M/M and that this can affect their antiviral potency...
  46. pmc HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase
    D A Davis
    HIV and AIDS Malignancy Branch, National Cancer Institute, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892 1906, USA
    Biochem J 346:305-11. 2000
    ....
  47. pmc A20/TNFAIP3 inhibits NF-κB activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein
    S Sakakibara
    Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Oncogene 32:1223-32. 2013
    ..By attenuating excessive and prolonged vFLIP-induced NF-κB activation that could be harmful to KSHV-infected cells, A20 likely has an important role in the pathogenesis of KSHV-associated diseases, in which vFLIP is expressed...
  48. pmc Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy
    Antonio Valentin
    Human Retrovirus Section, Basic Research Laboratory, National Cancer Institute, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 99:7015-20. 2002
    ..The properties of the virus reservoir in these cells should be considered in attempts to further optimize antiretroviral therapies...
  49. pmc A splenic marginal zone-like peripheral blood CD27+B220- B cell population is preferentially depleted in HIV type 1-infected individuals
    Matthew Morrow
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    AIDS Res Hum Retroviruses 24:621-33. 2008
    ....
  50. ncbi Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity
    Maria De La Luz Sierra
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 103:2452-9. 2004
    ..The differential processing of SDF-1alpha and SDF-1beta provides biologic significance to the existence of 2 splice forms of the chemokine and adds a tool to precisely regulate SDF-1's biologic activity by changes in specific activity...
  51. pmc An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease
    Thomas S Uldrick
    HIV and AIDS Malignancy Branch, National Cancer Institute Frederick, Frederick, MD, USA
    Clin Infect Dis 51:350-8. 2010
    ..Patients with KSHV-MCD develop fevers, wasting, hypoalbuminemia, cytopenias, and hyponatremia that are related to overproduction of KSHV-encoded viral interleukin (IL)-6 (vIL-6) and human IL-6 (hIL-6)...
  52. pmc The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 115:3017-24. 2010
    ..However, new therapeutic advances are needed for non-GCB DLBCL, which remains the important cause of lymphoma-specific death. This trial was registered at www.clinicaltrials.gov as NCT000019253...
  53. ncbi Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo
    Sabrina Villalba
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Leukoc Biol 74:880-8. 2003
    ..The inactivation of circulating SDF-1 may be critical in permitting local gradients to develop and direct cell trafficking...
  54. pmc Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus)
    M Paulose-Murphy
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:4843-53. 2001
    ..The patterns of viral gene expression offer insights into the replication and pathogenic strategies of HHV-8...
  55. ncbi Nanoparticle-Based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen
    Shixing Tang
    Lab of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 46:231-7. 2007
    ....
  56. ncbi Minimal reactivation of Kaposi's sarcoma-associated herpesvirus by corticosteroids in latently infected B cell lines
    J Paul Zoeteweij
    Dermatology Branch, National Cancer Institute, Bethesda, Maryland 20892 1908, USA
    J Med Virol 66:378-83. 2002
    ..Thus, our findings suggest that corticosteroids do not enhance the incidence and severity of KS in transplant recipients by direct cellular effects on KSHV reactivation...
  57. pmc Using noninvasive multispectral imaging to quantitatively assess tissue vasculature
    Abby Vogel
    National Institutes of Health, National Institute of Child Health and Human Development, Laboratory of Integrative and Medical Biophysics, Bethesda, Maryland 20892, USA
    J Biomed Opt 12:051604. 2007
    ....
  58. pmc Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary?
    Nadine Housri
    Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 116:273-83. 2010
    ..This review reports the published data regarding the interactions of HIV, AIDS, and antiretroviral therapy with radiotherapy and implications for the management of malignancies in patients with HIV...
  59. pmc Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells
    Antonio Valentin
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute Frederick, Maryland 21702 1201, USA
    AIDS Res Hum Retroviruses 26:79-88. 2010
    ..We conclude that the PI concentrations achieved in plasma could be suboptimal for full inhibition of virus spread in high P-gp cells, indicating that they may represent a pharmacological sanctuary for HIV-1...
  60. ncbi Key role for a viral lytic gene in Kaposi's sarcoma
    Robert Yarchoan
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    N Engl J Med 355:1383-5. 2006
  61. ncbi Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens
    Perdita Taylor
    Pediatric HIV Working Group, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Pediatrics 114:e235-42. 2004
    ....
  62. pmc Genetic organization and hypoxic activation of the Kaposi's sarcoma-associated herpesvirus ORF34-37 gene cluster
    Muzammel Haque
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1868, USA
    J Virol 80:7037-51. 2006
    ..Moreover, the activation of ORF36 by hypoxia might be exploited to develop targeted therapy for PEL, which arises in a hypoxic environment (pleural effusions)...
  63. ncbi Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus
    D A Davis
    HIV and AIDS Malignancy Branch, the Dermatology Branch, and the Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 97:3244-50. 2001
    ..These studies suggest that hypoxia is an inducer of KSHV replication. This process may play an important role in the pathogenesis of KS...
  64. ncbi Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus
    J P Zoeteweij
    Dermatology Branch, National Cancer Institute, Bethesda, MD 20892-1908, USA
    Blood 97:2374-80. 2001
    ....
  65. ncbi Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine
    S Jankelevich
    HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 183:1116-20. 2001
    ..CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression...
  66. ncbi Fluorometric determination of 2'-beta-fluoro-2',3'-dideoxyadenosine 5'-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes
    F Dai
    Laboratory of Medical Chemistry, Division of Basic Sciences, National Institutes of Health, Bethesda, Maryland 20892, USA
    Anal Biochem 288:52-61. 2001
    ..Application of this method to measure F-ddATP in peripheral blood mononuclear cells from HIV-infected patients treated with F-ddA at 3.2 mg/kg twice daily for 22 days shows F-ddATP levels which range from 1.5 to 3.5 pmol/10(6) cells...
  67. pmc Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia
    Muzammel Haque
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1868, USA
    J Virol 77:6761-8. 2003
    ..Thus, we demonstrated that a viral gene can be activated by hypoxia through activation of a functional viral HRE. To our knowledge, this is the first example of a functional HRE in a viral promoter...
  68. pmc Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
    Lokesh Jain
    Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Exp Clin Cancer Res 29:95. 2010
    ..We hypothesized that these toxicities would correspond to favorable outcome in these drugs, that HT and HFSR would coincide, and that VEGFR2 genotypic variation would be related to toxicity and clinical outcomes...
  69. pmc Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection
    Shixing Tang
    Lab of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Clin Vaccine Immunol 17:1244-51. 2010
    ..The data provide the foundation for development and refinement of new assays for improved p24 antigen testing as future tools for rapid and accurate diagnosis as part of early intervention strategies and estimations of incidence...
  70. ncbi A pilot study of cidofovir in patients with kaposi sarcoma
    Richard F Little
    HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Infect Dis 187:149-53. 2003
    ..This study does not provide proof of principle for the treatment of KS with CDV. However, it remains possible that antiherpesvirus therapy can be developed for herpes-induced tumors...
  71. pmc Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies
    C F Perno
    Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
    J Exp Med 171:1043-56. 1990
    ..Moreover, they are consistent with the notion that "enhancing" antibodies may serve to concentrate HIV onto CD4 receptors or, alternately, may act at other steps in the process of viral entry and replication...
  72. ncbi Measurement of in vitro specific-antibody synthesis
    R Yarchoan
    National Cancer Institute, Bethesda, Maryland, USA
    Curr Protoc Immunol . 2001
    ..Finally, after a 12-day incubation, the supernatant is harvested for assay...
  73. ncbi Treatment of gammaherpesvirus-related neoplastic disorders in the immunosuppressed host
    Richard F Little
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 40:163-71. 2003
    ..Novel therapy approaches include specific immune therapy and anti-angiogenesis approaches, now under development...
  74. ncbi Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones
    Elena A Semenova
    Laboratory of Molecular Pharmacology, Bldg 37, Room 5068, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Pharmacol 69:1454-60. 2006
    ..8 +/- 2.5 microM] exhibits weak cytoprotective activity against HIV-1(IIIB) in a cell-based assay. alpha-Hydroxytropolones represent a new family of inhibitors for the development of novel drugs against HIV infection...
  75. ncbi The use of antiretroviral therapy in patients undergoing treatment for HIV-related neoplastic disease
    Richard F Little
    Res Initiat Treat Action 9:19-25. 2003
  76. ncbi An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection
    Stephen M Smith
    Saint Michael s Medical Center, Newark, New Jersey 07102, USA
    J Biol Chem 278:44816-25. 2003
    ..We suggest the second coding exon of Tat as an example of a functionally constrained "epitope" whose elicited CTL response cannot be escaped by virus mutation without producing a virus that replicates poorly in vivo...
  77. ncbi Development of Kaposi's sarcoma at the site of a biopsy
    Robert Yarchoan
    N Engl J Med 347:763-4; author reply 763-4. 2002
  78. ncbi Poor specific T cell responses to human herpesvirus 8: A key to unleashing Kaposi sarcoma?
    Richard F Little
    J Infect Dis 194:1030-1. 2006
  79. ncbi Conservation of virally encoded microRNAs in Kaposi sarcoma--associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease
    Vickie Marshall
    Viral Epidemiology Section, AIDS Vaccine Program, Science Applications International Corporation Frederick, National Cancer Institute Frederick, Frederick, MD 21701, USA
    J Infect Dis 195:645-59. 2007
    ..Kaposi sarcoma (KS)-associated herpesvirus (KSHV) encodes 12 distinct microRNA genes, all of which are located within the latency-associated region that is highly expressed in all KSHV-associated malignancies...
  80. ncbi Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization
    Yasuhiro Koh
    Department of Hematology, Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, 1 1 1 Honjo, Kumamoto 860 8556, Japan
    J Biol Chem 282:28709-20. 2007
    ..Such a dual inhibition mechanism should lead to highly potent inhibition of HIV-1...